Immunocore Ltd - Articles and news items

Positive Phase I data for IMCgp100 in metastatic melanoma

Industry news / 6 June 2016 / Victoria White, Digital Content Producer

Immunocore has announced positive data from the first in human, Phase I clinical trial of its lead ImmTAC, IMCgp100…

First patient recruited in IMCgp100 uveal melanoma trial

Industry news / 30 March 2016 / Victoria White

The trial of IMCgp100 will include three Phase I escalation cohorts to determine the optimal dose for the Phase II study, which is expected to start in 2016…

Trial of IMCgp100, durvalumab and tremelimumab in melanoma starts

Industry news / 20 January 2016 / Victoria White

Immunocore has announced the start of the Phase Ib/II combination trial evaluating IMCgp100 with durvalumab and tremelimumab for the treatment of metastatic cutaneous melanoma…

Immunocore secures £205 million in Europe’s largest private life sciences financing

Industry news / 16 July 2015 / Victoria White

Immunocore Limited has announced the completion of a £205 million private financing round, allowing it to further accelerate its pipeline of ImmTACs…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+